Short Interest in iShares Biotechnology ETF (NASDAQ:IBB) Declines By 9.2%

iShares Biotechnology ETF (NASDAQ:IBB) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 10,090,000 shares, a decline of 9.2% from the January 15th total of 11,110,000 shares. Based on an average daily volume of 1,499,800 shares, the short-interest ratio is currently 6.7 days.

iShares Biotechnology ETF Stock Down 0.4 %

Shares of iShares Biotechnology ETF stock traded down $0.49 on Monday, hitting $136.55. The stock had a trading volume of 1,190,770 shares, compared to its average volume of 1,493,956. iShares Biotechnology ETF has a 52-week low of $123.60 and a 52-week high of $150.57. The company’s 50 day moving average price is $135.73 and its 200 day moving average price is $140.93.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

Institutional Trading of iShares Biotechnology ETF

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Huntington National Bank raised its stake in iShares Biotechnology ETF by 17.9% during the 3rd quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock valued at $153,000 after acquiring an additional 160 shares during the last quarter. National Bank of Canada FI increased its position in iShares Biotechnology ETF by 5.9% during the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 229 shares during the period. Avior Wealth Management LLC increased its position in iShares Biotechnology ETF by 438.2% during the 3rd quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock worth $470,000 after purchasing an additional 2,629 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its position in iShares Biotechnology ETF by 32.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after purchasing an additional 164,000 shares during the period. Finally, Main Management ETF Advisors LLC increased its position in iShares Biotechnology ETF by 2.5% during the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after purchasing an additional 14,535 shares during the period. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.